Literature DB >> 2982512

Degradation of type IV collagen by neoplastic human skin fibroblasts.

S Sheela, J C Barrett.   

Abstract

An assay for the degradation of type IV (basement membrane) collagen was developed as a biochemical marker for neoplastic cells from chemically transformed human skin fibroblasts. Type IV collagen was isolated from basement membrane of Syrian hamster lung and type I collagen was isolated from rat tails; the collagens were radioactively labelled by reductive alkylation. Both collagens were in the native form as shown by their low sensitivity to degradation by trypsin. The abilities of normal (KD) and chemically transformed (Hut-11A) human skin fibroblasts to degrade the collagens were studied. The normal cells released a collagenase into the medium which after activation by trypsin or oxidized glutathione degraded type I collagen. Hut-11A cells also produced a collagenolytic activity that degraded type I collagen; however, no activation of the medium was required for this activity. Type IV collagen was not degraded by medium conditioned with the normal (KD) cells with or without activation. In contrast, Hut-11A cells secreted an active collagenase into the medium that degraded type IV collagen extensively. Treatment of the medium from Hut-11A cells with trypsin resulted in only a loss of activity while treatment with oxidized glutathione was without effect. The degradation of type IV collagen by Hut-11A conditioned medium was linear for up to 1 h and the extent of degradation increased linearly with increasing amounts of conditioned medium. A cell-associated assay was performed by growing either normal or transformed cells in the presence of radioactively labelled type IV collagen and measuring the released soluble peptides in the medium. This assay also demonstrated that KD cells failed to synthesize an activity capable of degrading type IV collagen whereas Hut-11A cells degraded type IV collagen in a linear manner for up to 4 h. Human serum at very low concentrations, EDTA and L-cysteine inhibited the enzyme activity, whereas protease inhibitors like phenylmethyl sulfonyl fluoride, N-ethyl maleimide or soybean trypsin inhibitor did not inhibit the enzyme from Hut-11A cells. These results suggest that the ability to degrade specifically type IV collagen may be an important marker for neoplastic human fibroblasts and supports a role for this collagenase in tumor cell invasion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982512     DOI: 10.1093/carcin/6.2.173

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  Resistance to apoptosis, increased growth potential, and altered gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] exposure.

Authors:  Daryl E Pritchard; Susan Ceryak; Keri E Ramsey; Travis J O'Brien; Linan Ha; Jamie L Fornsaglio; Dietrich A Stephan; Steven R Patierno
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

2.  cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.

Authors:  Robert A Anders; Lisa M Yerian; Maria Tretiakova; Jon M Davison; Richard J Quigg; Peter H Domer; Jamie Hoberg; John Hart
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  Expression of transfected mutant beta-actin genes: alterations of cell morphology and evidence for autoregulation in actin pools.

Authors:  J Leavitt; S Y Ng; U Aebi; M Varma; G Latter; S Burbeck; L Kedes; P Gunning
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

4.  Relation between bladder cancer and protein oxidation.

Authors:  Ilker A Yilmaz; Tülay Akçay; Ufuk Cakatay; Ayşegül Telci; Süleyman Ataus; Veli Yalçin
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

5.  Oxidative stress parameters as biomarkers of bladder cancer development and progression.

Authors:  Paulina Wigner; Beata Szymańska; Michał Bijak; Ewa Sawicka; Paweł Kowal; Zofia Marchewka; Joanna Saluk-Bijak
Journal:  Sci Rep       Date:  2021-07-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.